Risk Assessment of Technology of Preparation Based on Recombinant Human Interleukin-7 and Its Perspective Validation
Keywords:Recombinant human interleukin-7, Quality management, Risk analysis, Critical control points, Validation
Background. Quality management is a very important activity of any industrial enterprise, especially when it comes to manufacturing products in health care (drugs, including medical immunobiological preparations, medical devices, cosmetics, dietary supplements, etc.). Risk-oriented thinking enables an organization to identify factors that may cause rejection of its processes and its quality management system for planned results to establish preventive controls to minimize negative impacts and the greatest possible shaft advantage of the opportunities as they arise. The logical continuation of the risk assessment is validation processes. This article is a fragment of the complex scientific and technical work on the development and standardization of biotechnology products based on recombinant human interleukin-7 (rhIL-7).
Objective. Justification for approaches to risk assessment in the technology for getting preparation based on rhIL-7 in the form of nasal spray and particularly risk assessment of the production process, and perspective validation of developed technologies.
Methods. The methodology of risk assessment according to ISO 14971:2009 “Medical devices. Guidelines for risk management” was used. Pharmacopoeial methods were used to control the process and product quality (potentiometric determination of pH, osmolality, sterility). The integrity of the filters was determined by the method according to the manometer producer.
Results. The work consistently study approaches to risk assessment in the technology for getting preparation based on rhIL-7 in the form of nasal spray and particularly risk assessment of the production process, and the validation of promising technologies developed. Selection of guidelines on risk assessment was conducted for Guidelines for Good Manufacturing Practices, ISO 9001:2015, ISO 13485:2005, and ISO 14971:2009. The greater acceptability of the use of the past two standards was showed. Technological production scheme is presented and qualitative approach to analyze the identified risks is applied. For the most critical stage of production (preparation of sterile solution) the validation process is conducted.Conclusions. The feasibility of risk assessment in the technology for getting preparation based on rhIL-7 in the form of nasal spray according to ISO 14971:2009 together with the system using risk analysis and critical control points is theoretically justified. It was found that the most critical step in the production is part of the preparation of a sterile solution, which includes the preparation of intermediate filtering and sterilizing drug. The conducted prospective validation of the most critical stages of the technology demonstrated its stability and compliance with established eligibility criteria.
Quality Management Systems. Requirements, DSTU ISO 9001:2015 (ISO 9001:2015, IDT), 2016 (in Ukrainian).
N.O. Vetyutneva et al., “Current status and trends of legal regulation in the field of drug quality”, Farmacevtychnyj Zhurnal, vol. 3, pp. 66–74, 2014 (in Ukrainian).
Ya.M. Derenska, “Quality management project in a pharmaceutical company”, Upravlinnya, Ekonomika ta Zabezpechennya Yakosti v Farmaciyi, vol. 3, pp. 10–16, 2011 (in Ukrainian).
Medicines. Good Manufacturing Practice, Guidance ST-N MOZU 42-4.0:2016 (approved by the Ministry of Health of Ukraine of 29.07.2016 no. 798), 2016 (in Ukrainian).
T.M. Lutsenko et al., “Justification of composition and technology of preparation based on recombinant human interleukin-7”, Academic Journal of Lviv Polytechnic National University, Ser. Chemistry, Materials Technology and their Application, vol. 841, pp. 174–180, 2016 (in Ukrainian).
T.M. Lutsenko et al., “Substantiation of parameters for standardization of drugs based on recombinant human interleukin-7”, Academic Journal of Lviv Polytechnic National University, Ser. Chemistry, Materials Technology and their Application, vol. 812, pp. 175–183, 2015 (in Ukrainian).
T.M. Lutsenko et al., “Methods of assessing biological activity of recombinant human interleukin-7 and stability study of the preparation on its basis”, Naukovi Visti NTUU KPI, no. 3, pp. 48–54, 2016 (in Ukrainian). doi: 10.20535/1810-0546.2016.3.65102
T.M. Lutsenko et al., “Validation of biological activity testing procedure of recombinant human interleukin-7”, Ukr. Biochem. J., vol. 89, no. 1, pp. 82–89, 2017. doi: 10.15407/ubj89.01.082
Medical Devices. Guidelines for Risk Management, DSTU ISO 14971:2009, 2012 (in Ukrainian).
State Pharmacopoeia of Ukraine, vol. 1, 2nd ed. Kharkiv, Ukraine: Ukrainian Scientific Pharmacopoeial Center for Quality of Medicines, 2015 (in Ukrainian).
Medical Devices. Quality Management Systems. Regulatory Requirements, DSTU ISO 13485:2005, 2007 (in Ukrainian).
LicenseCopyright (c) 2017 NTUU KPI Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under CC BY 4.0 that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work